JAMES A. KARBOSKI, B.S., PHARM.D. RESIDENT; PAUL J. GODLEY, PHARM.D.
This content is PDF only. Please click on the PDF icon to access.
To the editor: Conte and associates (1) recently reported the results of their pilot study evaluating inhaled pentamidine and reduced-dose intravenous pentamidine in treating Pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome (AIDS). They studied the hypothesis that administration of pentamidine by inhalation may reduce its adverse systemic effects while delivering the drug directly to the site of the infection. The only systemic side effects that occurred in the inhaled pentamidine group were neutropenia in two patients who had been receiving zidovudine and a rash in one patient. We report the case of a patient who had intermittent
KARBOSKI JA, GODLEY PJ. Inhaled Pentamidine and Hypoglycemia. Ann Intern Med. ;108:490. doi: 10.7326/0003-4819-108-3-490_1
Download citation file:
© 2019
Published: Ann Intern Med. 1988;108(3):490.
DOI: 10.7326/0003-4819-108-3-490_1